AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUL 1 - (NewsRx.com & NewsRx.net) -- Downregulated Bcl-2 or xIAP enhances the efficacy of breast cancer chemotherapy.
According to recent research from Portugal, "antiapoptotic genes such as bcl-2 or X-linked inhibitor of apoptosis proteins (xIAP) may be responsible for resistance to apoptosis induced by cytotoxic drugs. The aim of this study was to investigate if downregulation of bcl-2 or xIAP by RNA interference (RNAi) would sensitize MCF-7 cells to etoposide and doxorubicin. FITC-siRNAs uptake was verified by fluorescence microscopy and downregulation of Bcl-2 or xIAP was confirmed by Western blotting."
"Both siRNAs reduced the number of viable cells and increased cellular apoptosis. Treatment with siRNAs followed by treatment with etoposide or doxorubicin further reduced the number of viable cells, when compared to either of the treatments alone," reported R.T. Lima and colleagues, University of Porto, IPATIMUP.
...
Source: HighBeam Research, Downregulated Bcl-2 or xIAP enhances the efficacy of breast cancer...